Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Any believers in UPS who buy now can enjoy a generous dividend payment every quarter while waiting for a turnaround. Given ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Pfizer has taken a beating in recent years, and its market cap is now around $140 billion. But with the company still ...

We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing ...

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...